What is the recommended P21 dosage?

P21 dosing varies by experience level. Beginners typically start at 100mcg daily, moderate users at 300mcg daily, and aggressive protocols use 500mcg daily.

How do you reconstitute P21?

P21 typically comes in 5mg or 10mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of P21?

The half-life of P21 is ~3+ hours (estimated, plasma). This determines how frequently you need to dose for consistent blood levels.

P21

CognitiveInjection/NasalResearchGrade C~3+ hours (estimated, plasma) half-life

NootropicNeuroprotectionNeurogenesis4 weeks on / 4 weeks off

Benefits

Promoted hippocampal neurogenesis and dendritic maturation in multiple mouse models

Reduced tau hyperphosphorylation by 50-60% in triple transgenic Alzheimer's mice

Crosses the blood-brain barrier after peripheral administration

Enhanced spatial learning and reference memory in normal adult mice

Prevented synaptic loss and cognitive decline in Alzheimer's disease mouse models

Half-Life

~3+ hours

Route

Injection / Nasal

Frequency

Daily

Vial Sizes

5mg, 10mg

BAC Water

2mL

Safety Grade

Grade C

Open P21 Dosage Calculator

Calculate exact syringe units for your vial and dose

About P21

P21 (also designated P021) is a synthetic tetrapeptide derived from the biologically active region of human ciliary neurotrophic factor (CNTF), specifically amino acid residues 148-151. An adamantylated glycine group was added to the C-terminal to improve blood-brain barrier permeability and protect against enzymatic degradation by exopeptidases. Unlike full-length CNTF, which is too large to cross the blood-brain barrier and carries systemic side effects including weight loss and antibody formation, P21 was engineered to retain the neurotrophic benefits while eliminating these drawbacks. Its primary mechanism involves competitive inhibition of leukemia inhibitory factor (LIF) signaling, which normally acts as a brake on hippocampal neurogenesis. By suppressing LIF, P21 allows endogenous neurogenic processes to proceed more effectively, leading to increased BDNF expression, TrkB receptor activation, and downstream CREB phosphorylation. Preclinical evidence comes primarily from the laboratory of Dr. Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities. In 3xTg-AD mice (a triple transgenic Alzheimer's model), P21 reduced tau hyperphosphorylation by 50-60%, increased hippocampal neurogenesis approximately threefold, and prevented synaptic loss. In normal adult C57BL/6 mice, it enhanced spatial reference memory and promoted maturation of newly born neurons in the dentate gyrus. All existing data comes from animal studies. No Phase I, II, or III human clinical trials have been conducted, and the long-term safety profile in humans remains entirely unknown. This compound should be considered strictly experimental.

Who Should Consider P21

Researchers investigating CNTF/LIF pathway modulation and hippocampal neurogenesis
Individuals exploring experimental nootropics under medical supervision
Adults studying preclinical approaches to age-related cognitive decline
Those researching tau pathology and Alzheimer's disease interventions

How P21 Works

P21 competitively inhibits leukemia inhibitory factor (LIF) signaling in the hippocampus. LIF normally suppresses adult neurogenesis by activating the JAK/STAT3 pathway in neural stem cells, maintaining them in a quiescent state. By blocking this inhibitory signal, P21 releases the endogenous neurogenic brake, allowing neural progenitor cells in the subgranular zone of the dentate gyrus to proliferate and differentiate. This disinhibition leads to upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB. Downstream, BDNF/TrkB signaling increases CREB phosphorylation, a master regulator of synaptic plasticity that governs long-term potentiation, dendritic spine formation, and memory consolidation. P21 also reduces glycogen synthase kinase-3 beta (GSK-3B) activity, which decreases tau hyperphosphorylation — a hallmark of Alzheimer's disease pathology. The adamantylated glycine C-terminal modification provides resistance to exopeptidase degradation and enables the peptide to cross the blood-brain barrier after peripheral administration.

What to Expect

Weeks 1-2

No significant cognitive changes expected. Neurogenic processes are gradual. Any perceived effects during this window may be placebo. Animal studies show early increases in BDNF expression.

Weeks 2-4

In mouse models, measurable increases in hippocampal neurogenesis and dendritic maturation occur within this window. Anecdotal reports describe subtle improvements in focus and memory recall.

Weeks 4-6

Animal studies demonstrate peak neurogenic and cognitive effects by this period. Recommended cycle endpoint. Long-term mouse studies showed sustained benefits up to 18 months post-treatment, but human translatability is unknown.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	100mcg	Daily
Moderate	300mcg	Daily
Aggressive	500mcg	Daily

Note: CNTF-derived tetrapeptide (residues 148-151) with adamantylated glycine C-terminal cap. Crosses the blood-brain barrier. Intranasal or subcutaneous. Preclinical only — no human trials. Cycle 4 weeks on, 2-4 weeks off.

How to Inject P21

Intranasal: reconstitute and administer via nasal spray once daily in the morning. The intranasal route provides more direct CNS access via olfactory and trigeminal pathways and is the most commonly referenced route for this compound. Subcutaneous: inject into abdominal fat once daily, rotating injection sites. Start at the lowest dose (100 mcg) and titrate gradually. This is a preclinical research compound with no established human dosing guidelines — all doses are extrapolated from animal studies and anecdotal community reports.

Cycling Protocol

On Period

4 weeks

Off Period

4 weeks

Cycling recommended due to lack of long-term human safety data. Neurogenic effects are gradual and cumulative — do not expect acute cognitive changes. Some protocols suggest 2-4 weeks off between cycles. Discontinue if side effects emerge.

Pharmacokinetics

Half-Life

Bioavailability

Oral: demonstrated in mice (stable in GI fluid). Intranasal: direct CNS access via olfactory pathway. SC: assumed comparable to other small peptides.

Tmax

Not formally characterized in any species

Data Confidence

low

Source: Estimated plasma half-life >3 hours based on stability data (>90% stability in gastric juice, >97% in intestinal fluid at 37°C). No formal human PK studies published.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

No human safety data exists — all information derives from animal studies and anecdotal reports. Reported anecdotally: headache, mild fatigue, and transient brain fog during initial use. Full-length CNTF caused weight loss, cough, and antibody formation in human trials, but P21 was specifically designed to avoid these effects. No human toxicology studies have been performed.

Contraindications

Pregnancy or breastfeeding — no reproductive toxicology data exists
Individuals under 25 — brain development still ongoing
Active cancer or history of CNS tumors — neurogenic stimulation may carry theoretical risk
Known hypersensitivity to CNTF-derived compounds
Autoimmune neurological conditions — LIF pathway modulation may affect neuroimmune balance

Drug Interactions

Immunosuppressants (e.g., methotrexate, cyclosporine) — LIF pathway involvement in immune regulation may alter drug effects
Antidepressants (SSRIs, SNRIs) — both P21 and serotonergic drugs affect hippocampal neurogenesis; combined effects are unstudied
Anti-epileptic medications — neurogenic stimulation may theoretically lower seizure threshold; no data available
Other nootropic peptides (Semax, Selank, Dihexa) — no interaction data exists; use caution when stacking